Recursion Pharmaceuticals Shares Under Pressure as Nvidia Exits Investment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 hours ago
0mins
Should l Buy RXRX?
Source: Benzinga
- Investment Exit Impact: Nvidia's complete exit from its investment in Recursion Pharmaceuticals has pressured RXRX shares, reflecting a decline in market confidence that could hinder future fundraising efforts.
- Technical Indicators Show Weakness: Recursion's stock is currently positioned below all key moving averages, trading 18.2% below its 20-day SMA and 22.5% below its 50-day SMA, indicating sustained bearish momentum, necessitating caution from investors.
- Significant Price Decline: Over the past 12 months, Recursion Pharmaceuticals has experienced a steep decline of 68.19%, highlighting ongoing challenges the company faces, prompting investors to remain vigilant against potential risks.
- Poor Market Performance: As of Wednesday, Recursion shares were down 1.73% at $3.39, hitting a new 52-week low before recovering some losses, yet the overall trend remains weak, indicating market concerns about its future prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RXRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RXRX
Wall Street analysts forecast RXRX stock price to rise
6 Analyst Rating
2 Buy
4 Hold
0 Sell
Moderate Buy
Current: 3.460
Low
5.00
Averages
7.75
High
11.00
Current: 3.460
Low
5.00
Averages
7.75
High
11.00
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Recursion Schedules Q4 and Full Year 2025 Earnings Call
- Earnings Release Schedule: Recursion will announce its Q4 and full year 2025 financial results on February 25, 2026, before market open, which is expected to provide critical business updates that could influence investor confidence and market reactions.
- Investor Call: The company will host an earnings call on the same day at 8:00 AM ET, allowing investors and analysts to participate via live stream, enhancing transparency and fostering interaction with investors, potentially improving the company's image.
- Technological Platform Advantage: Recursion leverages its powerful Recursion OS platform, utilizing machine learning algorithms to generate one of the world's largest biological and chemical datasets, which could significantly enhance drug development efficiency and provide a competitive edge in the future market.
- Global Business Presence: With its headquarters in Salt Lake City and offices in Montreal, New York, London, and Oxford, Recursion demonstrates a strategic global footprint aimed at expanding its business growth potential through diversified market outreach.
See More
Recursion Pharmaceuticals Shares Under Pressure as Nvidia Exits Investment
- Investment Exit Impact: Nvidia's complete exit from its investment in Recursion Pharmaceuticals has pressured RXRX shares, reflecting a decline in market confidence that could hinder future fundraising efforts.
- Technical Indicators Show Weakness: Recursion's stock is currently positioned below all key moving averages, trading 18.2% below its 20-day SMA and 22.5% below its 50-day SMA, indicating sustained bearish momentum, necessitating caution from investors.
- Significant Price Decline: Over the past 12 months, Recursion Pharmaceuticals has experienced a steep decline of 68.19%, highlighting ongoing challenges the company faces, prompting investors to remain vigilant against potential risks.
- Poor Market Performance: As of Wednesday, Recursion shares were down 1.73% at $3.39, hitting a new 52-week low before recovering some losses, yet the overall trend remains weak, indicating market concerns about its future prospects.
See More
Palo Alto's Q2 Earnings Beat Estimates but Guidance Lowered
- Strong Earnings Report: Palo Alto Networks reported fiscal Q2 revenue of $2.59 billion, surpassing analyst expectations of $2.58 billion, indicating robust performance in the cybersecurity sector despite a challenging market environment.
- Earnings Beat: The company posted adjusted earnings of $1.03 per share, exceeding analyst estimates of 94 cents, demonstrating its continued profitability amidst fierce market competition.
- Guidance Downgrade: Palo Alto lowered its full-year adjusted earnings guidance from a range of $3.80 to $3.90 per share to a new range of $3.65 to $3.70, below the market estimate of $3.86, which may impact investor confidence.
- Stock Price Volatility: In pre-market trading, Palo Alto's shares fell 7.5% to $151.20, reflecting the market's negative reaction to the lowered guidance, potentially leading to subdued investor sentiment in the short term.
See More
Nvidia Exits Equity Stakes in RXRX and APLD, Shares Drop
- Stock Price Decline: Recursion Pharmaceuticals (RXRX) shares fell 13% in premarket trading on Wednesday, while Applied Digital (APLD) dropped 7.1%, primarily due to Nvidia (NVDA) disclosing in its latest 13F filing that it exited its equity stakes in both companies.
- Nvidia's Stake Change: Nvidia's previous filing had revealed a 7,716,050-share position in Applied Digital valued at approximately $177 million, and this exit could negatively impact market confidence, affecting investor expectations for both companies' futures.
- Market Reaction: Nvidia's stake change has drawn widespread attention in the market, particularly against the backdrop of volatility in tech stocks, leading to increased sensitivity to risk among investors and putting pressure on the stock prices of related companies.
- Industry Impact: This stock price decline not only reflects Nvidia's changing investment strategy but may also affect investor confidence in other tech companies, especially those involved in artificial intelligence and drug discovery sectors.
See More
Applied Digital and Recursion Pharmaceuticals Shares Decline, Attributed to Nvidia.
- Stock Performance: Applied Digital, Recursion Pharmaceuticals, and WeRide stocks experienced a decline early on Wednesday.
- Nvidia's Actions: Chip maker Nvidia has divested its stakes in all three companies mentioned.
See More
AI Drives Transformation in Genomics and Biological Manufacturing
- Genomics Advancement: Illumina secures U.S. Medicare reimbursement for its TruSight™ Oncology Comprehensive test, expected to significantly enhance the generation of clinically relevant genomic data, thereby advancing routine genomic profiling in cancer care.
- Liquid Biopsy Expansion: Guardant Health expands the availability of its Shield™ colorectal cancer screening test to U.S. military personnel and their families, enhancing the foundational data generation for precision medicine through ctDNA analysis.
- Drug Discovery Innovation: Recursion Pharmaceuticals leverages AI and machine learning to accelerate drug discovery, emphasizing platform scalability to reduce development time and costs, while attracting institutional interest from firms like ARK Investment Management.
- Spider Silk Production Plan: Kraig Biocraft Laboratories plans large-scale deployment of its transgenic silkworm platform in 2026, aiming to achieve a production capacity of 10 metric tons of recombinant spider silk per month by May, potentially opening new markets for high-performance materials.
See More
Recursion Schedules Q4 and Full Year 2025 Earnings Call
- Earnings Release Schedule: Recursion will announce its Q4 and full year 2025 financial results on February 25, 2026, before market open, which is expected to provide critical business updates that could influence investor confidence and market reactions.
- Investor Call: The company will host an earnings call on the same day at 8:00 AM ET, allowing investors and analysts to participate via live stream, enhancing transparency and fostering interaction with investors, potentially improving the company's image.
- Technological Platform Advantage: Recursion leverages its powerful Recursion OS platform, utilizing machine learning algorithms to generate one of the world's largest biological and chemical datasets, which could significantly enhance drug development efficiency and provide a competitive edge in the future market.
- Global Business Presence: With its headquarters in Salt Lake City and offices in Montreal, New York, London, and Oxford, Recursion demonstrates a strategic global footprint aimed at expanding its business growth potential through diversified market outreach.
See More
Recursion Pharmaceuticals Shares Under Pressure as Nvidia Exits Investment
- Investment Exit Impact: Nvidia's complete exit from its investment in Recursion Pharmaceuticals has pressured RXRX shares, reflecting a decline in market confidence that could hinder future fundraising efforts.
- Technical Indicators Show Weakness: Recursion's stock is currently positioned below all key moving averages, trading 18.2% below its 20-day SMA and 22.5% below its 50-day SMA, indicating sustained bearish momentum, necessitating caution from investors.
- Significant Price Decline: Over the past 12 months, Recursion Pharmaceuticals has experienced a steep decline of 68.19%, highlighting ongoing challenges the company faces, prompting investors to remain vigilant against potential risks.
- Poor Market Performance: As of Wednesday, Recursion shares were down 1.73% at $3.39, hitting a new 52-week low before recovering some losses, yet the overall trend remains weak, indicating market concerns about its future prospects.
See More
Palo Alto's Q2 Earnings Beat Estimates but Guidance Lowered
- Strong Earnings Report: Palo Alto Networks reported fiscal Q2 revenue of $2.59 billion, surpassing analyst expectations of $2.58 billion, indicating robust performance in the cybersecurity sector despite a challenging market environment.
- Earnings Beat: The company posted adjusted earnings of $1.03 per share, exceeding analyst estimates of 94 cents, demonstrating its continued profitability amidst fierce market competition.
- Guidance Downgrade: Palo Alto lowered its full-year adjusted earnings guidance from a range of $3.80 to $3.90 per share to a new range of $3.65 to $3.70, below the market estimate of $3.86, which may impact investor confidence.
- Stock Price Volatility: In pre-market trading, Palo Alto's shares fell 7.5% to $151.20, reflecting the market's negative reaction to the lowered guidance, potentially leading to subdued investor sentiment in the short term.
See More
Nvidia Exits Equity Stakes in RXRX and APLD, Shares Drop
- Stock Price Decline: Recursion Pharmaceuticals (RXRX) shares fell 13% in premarket trading on Wednesday, while Applied Digital (APLD) dropped 7.1%, primarily due to Nvidia (NVDA) disclosing in its latest 13F filing that it exited its equity stakes in both companies.
- Nvidia's Stake Change: Nvidia's previous filing had revealed a 7,716,050-share position in Applied Digital valued at approximately $177 million, and this exit could negatively impact market confidence, affecting investor expectations for both companies' futures.
- Market Reaction: Nvidia's stake change has drawn widespread attention in the market, particularly against the backdrop of volatility in tech stocks, leading to increased sensitivity to risk among investors and putting pressure on the stock prices of related companies.
- Industry Impact: This stock price decline not only reflects Nvidia's changing investment strategy but may also affect investor confidence in other tech companies, especially those involved in artificial intelligence and drug discovery sectors.
See More
Applied Digital and Recursion Pharmaceuticals Shares Decline, Attributed to Nvidia.
- Stock Performance: Applied Digital, Recursion Pharmaceuticals, and WeRide stocks experienced a decline early on Wednesday.
- Nvidia's Actions: Chip maker Nvidia has divested its stakes in all three companies mentioned.
See More
AI Drives Transformation in Genomics and Biological Manufacturing
- Genomics Advancement: Illumina secures U.S. Medicare reimbursement for its TruSight™ Oncology Comprehensive test, expected to significantly enhance the generation of clinically relevant genomic data, thereby advancing routine genomic profiling in cancer care.
- Liquid Biopsy Expansion: Guardant Health expands the availability of its Shield™ colorectal cancer screening test to U.S. military personnel and their families, enhancing the foundational data generation for precision medicine through ctDNA analysis.
- Drug Discovery Innovation: Recursion Pharmaceuticals leverages AI and machine learning to accelerate drug discovery, emphasizing platform scalability to reduce development time and costs, while attracting institutional interest from firms like ARK Investment Management.
- Spider Silk Production Plan: Kraig Biocraft Laboratories plans large-scale deployment of its transgenic silkworm platform in 2026, aiming to achieve a production capacity of 10 metric tons of recombinant spider silk per month by May, potentially opening new markets for high-performance materials.
See More
